explore -WSS

explore

author：explore 2025-09-27 07:51:55 - browse：4286

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Deliver public health messages at the right time

WSS

Black vets could get higher VA benefits if race not used in lung test

Prior authorization reform is both possible and imperative

Most antidepressants don't work on kids, teens, study finds

Dana Farber says 6 studies to be retracted and 31 corrected

Inaction leaves children at risk from dangerous chemotherapy drug

Deliver public health messages at the right time

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

New air purifier tech could be key to improving indoor air quality

Medicare bonuses could stop drug shortages under Senate plan

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Crowdfunding for medical bills sidesteps core problem, author says

Hepatitis C has a cure — but many Americans still lack access to it

Can gargling with Listerine treat gonorrhea of the mouth?

Hollywood unions extend contract negotiations for actors

Class action alleges UnitedHealth concealed DOJ probe

In age of alternative facts, a scholarly course on calling out crap

Microsoft launches AI tool for clinical documentation through Epic

Wikipedia

Microsoft launches AI tool for clinical documentation through Epic

Chemotherapy before breast cancer surgery might fuel metastasis

Brain MRIs reveal impact of 'toxic stress' on Black children

The inclusion problem at the heart of rehabilitation research

Future doctors need a strong humanities education

Empower primary care with adequate payments and technology

Wikipedia

leisure time

focus

leisure time